Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × HER2-positive Breast Cancer × Doxorubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 89 Lymphoma 58 Lymphoma, Large B-Cell, Diffuse 43 Precursor Cell Lymphoblastic Leukemia-Lymphoma 33 Sarcoma 31 Lymphoma, Non-Hodgkin 27 Hodgkin Disease 23 Leukemia 20 Burkitt Lymphoma 20 Lymphoma, Mantle-Cell 18 Neoplasms 16 Triple Negative Breast Neoplasms 14 Lymphoma, Follicular 14 Lymphoma, B-Cell 12 Carcinoma, Hepatocellular 12 Lymphoma, Large-Cell, Anaplastic 11 Neuroblastoma 10 Multiple Myeloma 10 Breast Neoplasms, Male 10 Neoplasm Metastasis 9 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8 Ovarian Neoplasms 8 Lymphoma, T-Cell, Peripheral 7 Lymphoma, T-Cell 7 Inflammatory Breast Neoplasms 7 Urinary Bladder Neoplasms 6 Osteosarcoma 6 Liposarcoma 6 Leiomyosarcoma 6 Fallopian Tube Neoplasms 6

Interventions

pertuzumab 2 Trastuzumab 2 Docetaxel 2 tucatinib 1 Protons 1 Paclitaxel 1 Fulvestrant 1 Enfuvirtide 1 Doxorubicin 1 Cyclophosphamide 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02379585 2018-04-24

STEFNE

Western Regional Medical Center

Phase 1/2 Terminated

8 enrolled 1 chart

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡